Amicus Capital Expenditures vs Free Cash Flow Analysis

FOLD Stock

USD 9.36 0.79 7.78%

Amicus Therapeutics financial indicator trend analysis is way more than just evaluating Amicus Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Amicus Therapeutics is a good investment. Please check the relationship between Amicus Therapeutics Capital Expenditures and its Free Cash Flow accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Amicus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.

Capital Expenditures vs Free Cash Flow

Capital Expenditures vs Free Cash Flow Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Amicus Therapeutics Capital Expenditures account and Free Cash Flow. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Amicus Therapeutics' Capital Expenditures and Free Cash Flow is -0.56. Overlapping area represents the amount of variation of Capital Expenditures that can explain the historical movement of Free Cash Flow in the same time period over historical financial statements of Amicus Therapeutics, assuming nothing else is changed. The correlation between historical values of Amicus Therapeutics' Capital Expenditures and Free Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capital Expenditures of Amicus Therapeutics are associated (or correlated) with its Free Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow has no effect on the direction of Capital Expenditures i.e., Amicus Therapeutics' Capital Expenditures and Free Cash Flow go up and down completely randomly.

Correlation Coefficient

-0.56

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Capital Expenditures

Capital Expenditures are funds used by Amicus Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Amicus Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Free Cash Flow

The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Most indicators from Amicus Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Amicus Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Amicus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.At present, Amicus Therapeutics' Issuance Of Capital Stock is projected to decrease significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 4.6 B, whereas Sales General And Administrative To Revenue is forecasted to decline to 1.19.

	2023	2024 (projected)
Extraordinary Items	90K	85.5K
Reconciled Depreciation	7.0M	6.3M

Extraordinary Items Reconciled Depreciation

Amicus Therapeutics fundamental ratios Correlations

	Total Assets	Total Stockholder Equity	Retained Earnings	Other Assets	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Other Current Liab	Total Current Liabilities	Accounts Payable	Cash	Short Term Investments	Other Current Assets	Common Stock	Property Plant Equipment	Short Long Term Debt Total	Other Liab	Property Plant And Equipment Net	Net Debt	Non Current Assets Total	Non Currrent Assets Other	Long Term Debt	Cash And Short Term Investments	Common Stock Total Equity	Non Current Liabilities Total	Property Plant And Equipment Gross
Total Assets		0.85	-0.61	0.49	0.69	0.58	0.88	0.4	0.76	0.49	0.65	0.63	0.49	0.72	0.59	0.62	0.46	0.53	0.49	0.87	0.55	0.63	0.85	0.69	0.93	0.49
Total Stockholder Equity	0.85		-0.34	0.37	0.47	0.38	0.59	0.08	0.52	0.7	0.38	0.79	0.22	0.52	0.44	0.33	0.42	0.37	0.24	0.73	0.49	0.34	0.83	0.48	0.62	0.26
Retained Earnings	-0.61	-0.34		-0.03	-0.99	-0.98	-0.78	-0.83	-0.94	-0.25	-0.87	-0.29	-0.9	-0.97	-0.89	-0.97	0.27	-0.89	-0.88	-0.28	-0.84	-0.95	-0.67	-0.98	-0.61	-0.94
Other Assets	0.49	0.37	-0.03		0.1	-0.11	0.45	-0.13	0.28	0.2	0.37	0.07	-0.05	0.11	0.03	0.09	0.59	0.0	-0.11	0.62	-0.01	0.12	0.26	0.1	0.52	-0.02
Common Stock Shares Outstanding	0.69	0.47	-0.99	0.1		0.98	0.84	0.8	0.97	0.34	0.88	0.38	0.88	1.0	0.9	0.96	-0.16	0.89	0.85	0.39	0.85	0.94	0.74	1.0	0.67	0.92
Other Stockholder Equity	0.58	0.38	-0.98	-0.11	0.98		0.74	0.82	0.91	0.3	0.81	0.35	0.89	0.97	0.89	0.94	-0.31	0.89	0.88	0.24	0.86	0.92	0.69	0.97	0.55	0.93
Total Liab	0.88	0.59	-0.78	0.45	0.84	0.74		0.68	0.91	0.26	0.86	0.33	0.68	0.84	0.67	0.81	0.36	0.64	0.64	0.78	0.59	0.81	0.7	0.83	0.93	0.67
Other Current Liab	0.4	0.08	-0.83	-0.13	0.8	0.82	0.68		0.77	-0.26	0.74	-0.02	0.86	0.78	0.65	0.81	-0.17	0.65	0.72	0.23	0.58	0.8	0.35	0.8	0.51	0.76
Total Current Liabilities	0.76	0.52	-0.94	0.28	0.97	0.91	0.91	0.77		0.34	0.94	0.3	0.82	0.96	0.87	0.92	0.02	0.85	0.75	0.54	0.82	0.9	0.71	0.97	0.76	0.88
Accounts Payable	0.49	0.7	-0.25	0.2	0.34	0.3	0.26	-0.26	0.34		0.21	0.63	0.01	0.37	0.41	0.21	0.06	0.39	0.17	0.31	0.49	0.19	0.62	0.34	0.24	0.27
Cash	0.65	0.38	-0.87	0.37	0.88	0.81	0.86	0.74	0.94	0.21		0.1	0.83	0.87	0.82	0.85	0.03	0.79	0.61	0.47	0.78	0.84	0.59	0.89	0.69	0.85
Short Term Investments	0.63	0.79	-0.29	0.07	0.38	0.35	0.33	-0.02	0.3	0.63	0.1		0.25	0.42	0.34	0.35	0.0	0.27	0.47	0.32	0.37	0.38	0.86	0.36	0.4	0.15
Other Current Assets	0.49	0.22	-0.9	-0.05	0.88	0.89	0.68	0.86	0.82	0.01	0.83	0.25		0.86	0.86	0.92	-0.35	0.83	0.83	0.15	0.82	0.9	0.62	0.86	0.53	0.88
Common Stock	0.72	0.52	-0.97	0.11	1.0	0.97	0.84	0.78	0.96	0.37	0.87	0.42	0.86		0.9	0.94	-0.13	0.88	0.83	0.41	0.85	0.92	0.77	1.0	0.68	0.9
Property Plant Equipment	0.59	0.44	-0.89	0.03	0.9	0.89	0.67	0.65	0.87	0.41	0.82	0.34	0.86	0.9		0.84	-0.27	0.99	0.71	0.26	0.97	0.8	0.69	0.89	0.52	0.96
Short Long Term Debt Total	0.62	0.33	-0.97	0.09	0.96	0.94	0.81	0.81	0.92	0.21	0.85	0.35	0.92	0.94	0.84		-0.26	0.82	0.93	0.28	0.77	1.0	0.71	0.94	0.66	0.87
Other Liab	0.46	0.42	0.27	0.59	-0.16	-0.31	0.36	-0.17	0.02	0.06	0.03	0.0	-0.35	-0.13	-0.27	-0.26		-0.3	-0.41	0.82	-0.31	-0.23	0.02	-0.15	0.5	-0.32
Property Plant And Equipment Net	0.53	0.37	-0.89	0.0	0.89	0.89	0.64	0.65	0.85	0.39	0.79	0.27	0.83	0.88	0.99	0.82	-0.3		0.71	0.22	0.95	0.77	0.62	0.88	0.48	0.98
Net Debt	0.49	0.24	-0.88	-0.11	0.85	0.88	0.64	0.72	0.75	0.17	0.61	0.47	0.83	0.83	0.71	0.93	-0.41	0.71		0.11	0.64	0.94	0.68	0.82	0.53	0.74
Non Current Assets Total	0.87	0.73	-0.28	0.62	0.39	0.24	0.78	0.23	0.54	0.31	0.47	0.32	0.15	0.41	0.26	0.28	0.82	0.22	0.11		0.21	0.3	0.51	0.39	0.86	0.2
Non Currrent Assets Other	0.55	0.49	-0.84	-0.01	0.85	0.86	0.59	0.58	0.82	0.49	0.78	0.37	0.82	0.85	0.97	0.77	-0.31	0.95	0.64	0.21		0.73	0.7	0.85	0.43	0.91
Long Term Debt	0.63	0.34	-0.95	0.12	0.94	0.92	0.81	0.8	0.9	0.19	0.84	0.38	0.9	0.92	0.8	1.0	-0.23	0.77	0.94	0.3	0.73		0.73	0.92	0.68	0.83
Cash And Short Term Investments	0.85	0.83	-0.67	0.26	0.74	0.69	0.7	0.35	0.71	0.62	0.59	0.86	0.62	0.77	0.69	0.71	0.02	0.62	0.68	0.51	0.7	0.73		0.73	0.69	0.55
Common Stock Total Equity	0.69	0.48	-0.98	0.1	1.0	0.97	0.83	0.8	0.97	0.34	0.89	0.36	0.86	1.0	0.89	0.94	-0.15	0.88	0.82	0.39	0.85	0.92	0.73		0.65	0.91
Non Current Liabilities Total	0.93	0.62	-0.61	0.52	0.67	0.55	0.93	0.51	0.76	0.24	0.69	0.4	0.53	0.68	0.52	0.66	0.5	0.48	0.53	0.86	0.43	0.68	0.69	0.65		0.49
Property Plant And Equipment Gross	0.49	0.26	-0.94	-0.02	0.92	0.93	0.67	0.76	0.88	0.27	0.85	0.15	0.88	0.9	0.96	0.87	-0.32	0.98	0.74	0.2	0.91	0.83	0.55	0.91	0.49

Click cells to compare fundamentals

Amicus Therapeutics Account Relationship Matchups

Amicus Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	850.2M	886.5M	905.1M	724.2M	777.9M	451.1M
Total Stockholder Equity	476.4M	286.4M	307.4M	123.0M	160.2M	168.7M
Retained Earnings	(1.8B)	(2.0B)	(2.3B)	(2.5B)	(2.7B)	(2.5B)
Other Assets	51.3M	65.4M	47.4M	42.2M	48.6M	41.8M
Common Stock Shares Outstanding	240.4M	258.9M	271.4M	289.1M	295.2M	309.9M
Liabilities And Stockholders Equity	850.2M	886.5M	905.1M	724.2M	777.9M	473.3M
Other Stockholder Equity	2.2B	2.3B	2.6B	2.7B	2.8B	3.0B
Total Liab	373.8M	600.1M	597.8M	601.1M	617.7M	648.6M
Other Current Liab	1.3M	87.7M	103.5M	100.6M	123.5M	129.7M
Total Current Liabilities	128.8M	129.7M	146.0M	139.0M	167.7M	176.1M
Accounts Payable	120.4M	17.1M	21.5M	15.4M	15.1M	21.1M
Cash	142.8M	163.2M	245.2M	148.8M	247.0M	259.3M
Short Term Investments	309.9M	320.0M	237.3M	144.8M	39.2M	37.2M
Other Current Assets	20.0M	59.4M	69.7M	40.2M	49.5M	52.0M
Common Stock	2.6M	2.7M	2.8M	2.8M	2.9M	3.1M
Property Plant Equipment	47.7M	43.9M	42.5M	30.8M	35.4M	37.2M
Short Long Term Debt Total	210.2M	441.7M	440.1M	452.1M	445.1M	467.3M
Other Liab	41.9M	35.6M	19.1M	18.5M	21.3M	20.2M
Property Plant And Equipment Net	81.0M	67.2M	63.1M	60.3M	58.0M	60.9M
Net Debt	67.4M	278.5M	194.9M	303.3M	198.1M	208.0M
Non Current Assets Total	330.1M	307.1M	308.3M	300.4M	294.8M	204.5M
Non Currrent Assets Other	28.3M	19.1M	24.4M	10.0M	18.6M	19.5M
Long Term Debt	149.5M	389.3M	389.4M	392.0M	387.9M	407.3M
Cash And Short Term Investments	452.7M	483.3M	482.5M	293.6M	286.2M	251.3M
Common Stock Total Equity	2.6M	2.7M	2.8M	2.8M	3.2M	3.4M
Non Current Liabilities Total	245.0M	470.5M	451.8M	462.1M	450.0M	243.4M
Property Plant And Equipment Gross	81.0M	67.2M	83.0M	82.6M	83.4M	87.6M
Total Current Assets	520.1M	579.5M	596.8M	423.8M	483.1M	293.7M
Accumulated Other Comprehensive Income	2.8M	8.2M	5.0M	(12.1M)	5.2M	5.5M
Net Tangible Assets	255.6M	65.6M	86.6M	(97.8M)	(112.4M)	(106.8M)
Net Receivables	33.3M	46.9M	52.7M	66.2M	87.6M	92.0M
Retained Earnings Total Equity	(1.8B)	(2.0B)	(2.3B)	(2.5B)	(2.3B)	(2.2B)
Capital Surpluse	2.2B	2.3B	2.6B	2.7B	3.1B	1.7B
Inventory	14.0M	19.6M	26.8M	23.8M	59.7M	62.7M
Deferred Long Term Liab	14.0M	12.3M	10.8M	9.6M	8.6M	8.2M
Non Current Liabilities Other	81.5M	68.9M	51.6M	60.5M	13.3M	12.6M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

When determining whether Amicus Therapeutics is a strong investment it is important to analyze Amicus Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amicus Therapeutics' future performance. For an informed investment choice regarding Amicus Stock, refer to the following important reports:

How To Invest In Amicus

Details

Is Amicus Stock a good investment?

Details

What is Amicus Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Amicus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For information on how to trade Amicus Stock refer to our How to Trade Amicus Stock guide.

You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amicus Therapeutics. If investors know Amicus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amicus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.34)

Revenue Per Share

1.629

Quarterly Revenue Growth

0.367

Return On Assets

0.0116

Return On Equity

(0.67)

The market value of Amicus Therapeutics is measured differently than its book value, which is the value of Amicus that is recorded on the company's balance sheet. Investors also form their own opinion of Amicus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Amicus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amicus Therapeutics' market value can be influenced by many factors that don't directly affect Amicus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Amicus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amicus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amicus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Amicus Capital Expenditures vs Free Cash Flow Analysis

Capital Expenditures vs Free Cash Flow

Capital Expenditures vs Free Cash Flow Correlation Analysis

Correlation Coefficient

Capital Expenditures

Free Cash Flow

Amicus Therapeutics fundamental ratios Correlations

Amicus Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Amicus Therapeutics fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock	+ 1.0	Common Stock Shares Outstanding
Common Stock Total Equity	+ 1.0	Common Stock Shares Outstanding
Common Stock Total Equity	+ 1.0	Common Stock
Long Term Debt	+ 1.0	Short Long Term Debt Total
Property Plant And Equipment Net	+ 0.99	Property Plant Equipment
Other Stockholder Equity	+ 0.98	Common Stock Shares Outstanding

Common Stock Shares Outstanding	- 0.99	Retained Earnings
Common Stock Total Equity	- 0.98	Retained Earnings
Other Stockholder Equity	- 0.98	Retained Earnings
Short Long Term Debt Total	- 0.97	Retained Earnings
Common Stock	- 0.97	Retained Earnings
Long Term Debt	- 0.95	Retained Earnings